HC Wainwright Issues Positive Forecast for SGMT Earnings

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Analysts at HC Wainwright increased their Q1 2025 EPS estimates for Sagimet Biosciences in a note issued to investors on Thursday, March 13th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($1.00) for the quarter, up from their prior estimate of ($1.08). HC Wainwright currently has a "Buy" rating and a $32.00 target price on the stock. The consensus estimate for Sagimet Biosciences' current full-year earnings is ($1.60) per share. HC Wainwright also issued estimates for Sagimet Biosciences' Q2 2025 earnings at ($1.22) EPS, Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($4.86) EPS, FY2026 earnings at ($5.77) EPS, FY2027 earnings at ($5.44) EPS, FY2028 earnings at ($3.74) EPS and FY2029 earnings at ($2.29) EPS.

Separately, Oppenheimer started coverage on shares of Sagimet Biosciences in a report on Friday, December 6th. They issued an "outperform" rating and a $30.00 price objective for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $23.00.

Sagimet Biosciences Trading Up 4.4 %

Sagimet Biosciences stock traded up $0.17 during mid-day trading on Monday, reaching $4.02. The company's stock had a trading volume of 259,982 shares, compared to its average volume of 860,055. The firm has a market cap of $123.31 million, a price-to-earnings ratio of -2.81 and a beta of 2.57. The business has a 50 day moving average price of $4.15 and a 200-day moving average price of $4.47. Sagimet Biosciences has a twelve month low of $2.39 and a twelve month high of $7.38.

Remove Ads

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.15.

Institutional Investors Weigh In On Sagimet Biosciences

A number of hedge funds have recently added to or reduced their stakes in SGMT. Barclays PLC lifted its stake in Sagimet Biosciences by 14.3% in the third quarter. Barclays PLC now owns 57,230 shares of the company's stock valued at $159,000 after buying an additional 7,178 shares during the last quarter. Geode Capital Management LLC lifted its stake in Sagimet Biosciences by 56.7% in the third quarter. Geode Capital Management LLC now owns 252,298 shares of the company's stock valued at $699,000 after buying an additional 91,246 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Sagimet Biosciences by 66.2% in the third quarter. JPMorgan Chase & Co. now owns 72,017 shares of the company's stock valued at $199,000 after buying an additional 28,690 shares during the last quarter. Jacksonville Wealth Management LLC bought a new stake in Sagimet Biosciences in the fourth quarter valued at $45,000. Finally, Stoneridge Investment Partners LLC lifted its stake in Sagimet Biosciences by 22.2% in the fourth quarter. Stoneridge Investment Partners LLC now owns 20,836 shares of the company's stock valued at $94,000 after buying an additional 3,780 shares during the last quarter. 87.86% of the stock is currently owned by institutional investors.

Sagimet Biosciences Company Profile

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.